UK - English
Select a Country

MEETING PATIENTS’ NEEDS

Our discovery and development process always begins with the patient. We ask these important questions: How are patient needs not currently being met? How can we improve their treatment options? How can we work toward better outcomes? Starting with patient needs helps us focus our efforts and keeps our eye on our goal: to help patients improve their health and their lives.

focusimg1_03

Our discovery and development efforts are focused on a core set of therapeutic areas where we have proven expertise and where we believe we can have an even greater impact on the disease and how it is managed. These core areas of focus include hepatitis C (HCV), neuroscience, immunology, oncology, renal disease and women’s health.

Read more about medicines we’re developing in these areas in Pipeline.


ADDRESSING SERIOUS HEALTH ISSUES

Hepatitis C Virus (HCV)

Our antiviral programme is focused on developing treatments for hepatitis C (HCV), a disease that affects more than 170 million people worldwide, with approximately 4 million people newly infected each year. HCV infections can potentially lead to long-term complications. AbbVie scientists are working to transform current treatment practices by investigating a new treatment regimen that is interferon-free for patients with genotype 1 HCV. We have several compounds for HCV in late-stage development, including protease, non-nucleoside polymerase and NS5A inhibitors.


Neuroscience/Pain

We are conducting innovative research on compounds that target receptors in the brain. These receptors help regulate pain, mood, memory and other neurological functions. We have a number of early and advanced investigational compounds in human studies for conditions such as schizophrenia, chronic pain, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS)—all of which affect millions of people worldwide.


Immunology

AbbVie's scientific experience with our biologics serves as a strong foundation for continuing research in immunology. AbbVie is investigating a number of additional diseases, including spondyloarthropathies, hidradenitis suppurativa and uveitis, all of which are in late-stage development. Our early discovery programmes are focused on the investigation of both targeted oral therapies and biologics. AbbVie scientists are innovators in the antibody therapeutic field, with the creation and development of proprietary Dual-Variable Domain antibodies (DVD-Ig), which allows for creating combination biologics to simultaneously target multiple pathways responsible for disease progression.


Oncology

Our oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. We are investigating both small- and large-molecule approaches, and our internal research efforts are balanced with external collaborations across industry, academia and government. AbbVie's oncology pipeline includes multiple new molecules in clinical trials, being studied in more than 15 different cancers and tumour types, including some of the most widespread and difficult to treat cancers such as multiple myeloma and chronic lymphocytic leukaemia.


Renal Disease

Chronic kidney disease (CKD), the progressive loss of kidney function, affects 50 million people in the U.S. and Europe alone. CKD is on the rise, driven by higher rates of diabetes, obesity and hypertension. AbbVie’s renal care pipeline includes potential therapies for CKD and for acute kidney injury, a complication of major surgery that affects 1.2 million people at risk annually.


Women’s Health

AbbVie is currently focused on developing a compound for endometriosis and uterine fibroids, which each affect more than 16 million women worldwide. Both are highly prevalent conditions associated with a number of symptoms including pain and infertility. Because these conditions are under treated, we have the potential to fill a significant therapeutic void.

Leave the UK site

The Abbvie Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Abbvie Internet site that you have requested may be in a language that differs from your country of origin.

The Abbvie Internet site that you have requested may not be optimised for your screen size.

Do you wish to continue to this Abbvie site?

Exit abbvie.co.uk

The product-specific Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals and other products or uses of those products that are not approved in other countries or regions. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The product-specific Internet site that you have requested may not be optimized for your screen size.

Do you wish to continue to this product-specific site?

AXCOR121934c(2) - DECEMBER 2014

Exit abbvie.co.uk

Notice

The “Yes” link below will take you out of AbbVie family of websites

Links which take you out of AbbVie worldwide web sites are not under the control of AbbVie, and AbbVie are not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?